lobbying_activities: 1913308

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1913308	fad97564-4a35-4e4d-8b33-a534ed83b9c1	Q4	THE INGRAM GROUP LLC	400577737	ELI LILLY AND COMPANY	2016	fourth_quarter	PHA	S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2015. H.R.34, 21st Century Cures Act (P.L.114-255). H.R.2028, Further Continuing and Security Assistance Appropriations Act, 2017 (P.L.114-254). General issues related to the biopharmaceutical and pharmaceutical industries.	HOUSE OF REPRESENTATIVES,SENATE	40000		0	0	2017-01-14T11:44:54-05:00